Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Barclays Initiates Coverage On CinCor Pharma with Overweight Rating, Announces Price Target of $22

Author: Benzinga Newsdesk | December 07, 2022 07:46am
Barclays analyst Leon Wang initiates coverage on CinCor Pharma (NASDAQ:CINC) with a Overweight rating and announces Price Target of $22.

Posted In: CINC